Trump confirms Makary out at FDA
President Donald Trump confirmed on Tuesday that Marty Makary would be leaving his post atop the U.S. Food and Drug Administration.
While speaking to reporters on the White House lawn Tuesday, Trump said Makary would be leaving. He said FDA deputy commissioner Kyle Diamantes will take over as the adminsitration seeks a new leader of the federal agency.
“He was having some difficulty,” Trump said. “Marty is a terrific guy, but he’s going to go and lead a good life.”
Trump did not specify what kind of difficulty Makary experienced. Several reports circulated that there was an internal dispute over approval for flavored vapes at the FDA. The Wall Street Journal reported that Trump pressured Makary to approve fruit-flavored vapes, but he was hesitant to do so.
Trump said many people are seeking the job atop the agency.
Makary was expected to testify on Capitol Hill Wednesday to present the FDA’s budget for the upcoming fiscal year. Diamantes is expected to take his place.
Makary was confirmed to lead the FDA in March 2025. Since then, he’s sought to make several changes to the agency’s policies and change organizational structure. Makary sought to limit antidepressants for pregnant women and ban kratom byproducts.
“He’s a friend of mine, he’s a wonderful man and he’s going to be off,” Trump said of Makary.
Latest News Stories
Bondi defends Epstein files release, denies Trump involvement
Federal jury convicts Spokane ICE protesters as questions remain about local charges
Cost uncertainty follows prescription price cap bill in Senate
Trump making final determination on Iranian ceasefire deal
Nevada candidates call for fraud enforcement, healthcare aid
Sherill calls on ICE to close New Jersey detention center
Illinois Quick Hits: Chicago mayor, delegation meet pope
USDA plan rallies around American cotton farmers
Manhattan Board Approves Federal Grant Plan and Teacher Evaluation Agreement
WATCH: Experts say increased spending doesn’t mean better students
‘Taxpayers deserve to know’: Experts applaud Trump’s drug price transparency expansion
Tourism spending, Springfield investment bill considered as budget deadline nears
DOJ sues four states over denial of undercover license plates to federal agents
Constitutional questions raised over digital age verification bill